Tetrahydrobiopterin (BH 4 ) is a cofactor for aromatic amino acid hydroxylases and nitric oxide synthase. The biosynthetic pathway of BH 4 from 6-pyruvoyl-tetrahydropterin (PPH 4 ) includes two reduction steps catalyzed by sepiapterin rcductasc (SPR). PP1I 4 is reduced to 6-( 1 '-oxo-2'-hydroxypiOpyl)-tetrahydropterin (l'-OXPH 4 ) or 6-( r-hydroxy-2'-oxopropyl)-tetrahydropterin (2'-OXPH 4 ), which is further converted to BH 4 . However, patients with SPR deficiency show normal urinary excretion of pterins without hyperphenylalaninemia, suggesting the existence of another BH 4 biosynthetic pathway, which is not concerned with SPR in humans. Blau et al. proposed a BH 4 biosynthetic salvage pathway containing nonenzymatic conversion of l'-OXPH 4 to sepiapterin. In this study, the possibility of the nonenzymatic conversion of l'-OXPH 4 to sepiapterin was examined by using silkworm carbonyl reductase (CR 1) and human monomeric carbonyl reductase. Since l'-OXPH 4 has been suggested to be nonenzymatically converted into sepiapterin, in an incubation mixture containing PPH 4 and silkworm CR I, sepiapterin was determined by its derivative as biopterin. No sepiapterin was detected in the incubation mixture when the mixture, containing 800 pmol of l'-OXPH 4 , was further incubated at 37°C for 2 h in darkness. This result suggests that the rate of nonenzymatic formation of sepiapterin from l'-OXPH 4 is quite low. The findings obtained here indicate that the proposed pathway in which a nonenzymatic conversion of l'-OXPH 4 to sepiapterin occurs may be difficult or unlikely to proceed in humans.
Introduction
Tetrahydrobiopterin is a cofactor for aromatic amino acid hydroxylases (1, 2) , which catalyze the initial steps in phenylalanine degradation in the liver and the rate-limiting steps in the biosynthesis of catecholamine and indoleamine neurotransmitters in the brain. It is also required for nitric oxide synthase, which generates nitric oxide, a messenger molecule involved in various processes ¡11 many tissues (3, 4) . The pathway of the de novo biosynthesis of BH 4 from GTP involves GTP cyclohydrolasc I (EC 3.5.4.16). 6-pyruvoyl-tetrahydropterin (PPH 4 ) synthase (EC 4.6.1.10). and sepiapterin reductase (SPR, EC 1.1.1.153). SPR catalyzes the last step of the biosynthesis, in which the diketo group on the side chain of Ρ PI I4 is converted into the corresponding diol form in BH 4 . PPH 4 is first reduced to 6-( 1 '-hydroxy-2'-oxopropylj-tetrahydropterin (2'-OXPH 4 ) or 6-( l'-oxo-2'-hydroxypropyl)-tetrahydropterin ( l'-OXPH 4 ), and then both tetrahydropterin intermediates are reduced to BH 4 (5-7). The formation of l'-OXPH 4 in the first reduction is catalyzed by PPH 4 reductase (8), which has been shown to be identical to aldose reductase in the human 4 by aldose reductase and is nonenzymatically converted into sepiapterin, which is then reduced to BH 2 by carbonyl reductase.
We previously discovered two carbonyl reductases (CRI and CRII) that are involved in the formation of BH 4 from PPH 4 in the fat body of the lemon mutant and the normal strain of the silkworm, Bombyx mori (13) (14) (15) . The silkworm carbonyl reductases differ from SPR and human carbonyl reductase because CRI catalyzes the reduction of the 2'-keto group of both PPH 4 and 2'-OXPH 4 and CRII reduces the l'-keto group of PPH 4 and Γ-ΟΧΡΗ 4 ( 1 5). Recently, we reported a new SPR-unrelated BH 4 formation route from PPH 4 . in which human aldo-keto reductase (AKR)1C3 and AKR1B1 work in concert (16) . In order to elucidate the nonenzymatic conversion of l'-OXPH 4 to sepiapterin, we examined the determination of biopterin after iodine oxidation of dihydrobiopterin, which was synthesized from sepiapterin by human carbonyl reductase. The data shows that the rate of the nonenzymatic formation of sepiapterin from l'-OXPII 4 is quite low, which suggests that the formation of sepiapterin from l'-OXPH 4 in the proposed pathway is difficult to achieve.
Materials and Methods
Chemicals and enzymes BH 4 and sepiapterin were purchased from Dr. Schircks (Jona, Switzerland). Dihydroneopterin triphosphate (NH 2 TP) was synthesized enzymatically from GTP by the method of Yoshioka et al. (17) using purified GTP cyclohydrolase I from chicken liver ( 1 8). The 1 '-OXPH 4 standard was prepared as described previously (13) . The PPH4 synthase was purified from chicken liver by the method of Takikawa et al. [19] . Silkworm carbonyl reductase (CR I) was prepared as described previously (15) . Purified human monomelic carbonyl reductase was kindly supplied by Dr. A. Hara (Gifu Pharmaceutical Univ.). Other chemicals were of analytical grade and obtained from commercial sources.
Assay of Γ-Ο.ΧΡΗ4 producing activity The analysis of l'-OXPH 4 was performed by HPLC with electrochemical detection, as described previously (15) . The quantitative analysis of tetrahydropterins in the reaction mixture was conducted with BH 4 as a standard.
A na/vs is of biopterin The nonenzymatic formation of sepiapterin from Γ-OXPH 4 was examined by determining it as biopterin, as described below. l'-OXPH 4 (8 μΜ) was initially produced by incubation with PPH 4 and CR 1 in the absence of dithiothreitol in a final volume of 100 μΐ, and the reaction mixture was incubated at 37°C for 2 h in darkness. Since human monomeric carbonyl reductase reduces sepiapterin to dihydrobiopterin (BH 2 ) (20), the enzyme (2 μg) was added to the reaction mixture and further incubated at 37°C for 40 min. The reaction was stopped by the addition of 10 ml of a 20% trichloroacetic acid solution and 20 μΐ of an iodine solution (1% I 2 , 2% KI). The amount of biopterin in the resulting supernatant was measured by HPLC with fluorometric detection (21) .
Results and Discussion
SPR deficiency can be diagnosed only by the investigation of pterin metabolites in cerebrospinal Huid (CSF), in which the neopterin level is normal but those of biopterin and BH 2 are high (11) . Furthermore, patients with SPR deficiency display normal urinary pterins without hyperphenylalaninemia. In order to explain these facts of SPR deficiency, Blau et al. (11) proposed a BH 4 biosynthetic salvage pathway, such as PPH 4 -» Γ-ΟΧΡΗ 4 sepiapterin -> BH 2 -> BH 4 .
In this pathway. l'-OXPH 4 is produced from PPH 4 by aldose reductase and is nonenzymatically converted to sepiapterin. which is then reduced to BH 2 by carbonyl reductase. The final reduction of ΒΗτ to BH 4 is catalyzed by dihydrofolatc reductase (DHFR, EC 1.5.1.3) (10) (11) (12) . The activity of DHFR in the brain is approximately 10-fold lower than that in the liver, suggesting that the reduction step proceeds slowly. For this reason, a patient with SPR deficiency may show progressive psychomotor retardation and dystonia.
In order to elucidate the nonenzymatic conversion from 1 '-OXPH 4 to sepiapterin, sepiapterin was determined by measurement of biopterin, after iodine oxiPteridines/Vol. 1 6/N0. 1 dation of dihydrobiopterin, which was synthesized from sepiapterin by human carbonyl reductase. No sepiapterin was detected in the incubation mixture when the mixture containing 800 pmol of l'-OXPH 4 was further incubated at 37°C for 2 h in darkness (Figs. 1 and 2 ) .
The result suggests that the rate of the nonenzymatic formation of sepiapterin from l'-OXPH 4 is quite 1 -OX-PH4 a reasonable explanation for the characterization of SPR deficiency, such as abnormal CSF metabolites and normal urinary pterins without hyperphenylalaninemia. However, the amount of BH 4 in the brain is insufficient to exhibit its physiological function because of the low expression of AKR1C3 mRNA (22) . For this reason, a patient with SPR deficiency may show progressive psychomotor retardation and dystonia.
• small. The present result indicates that the rate of the nonenzymatic conversion of l'-OXPH 4 to sepiapterin is very low, and suggests that the formation of sepiapterin from l'-OXPH 4 in the proposed pathway is difficult to achieve.
We have reported that the new synthetic pathway of BH 4 from PPH 4 by the combination of human AKR 1 C3 and AKR1 Β 1 probably proceeds more rapidly than the above salvage pathway containing a nonenzymatic step ( 16) . Additionally, this pathway provides Figure 2 . The noncnzymatic formation of sepiapterin from Γ-ΟΧΡΗ4. !'-OXPH 4 (8 μΜ) was initially produced by incubation with PPH 4 and CR I in the absence of dithiothreitol in a final volume of 100 μΐ, and the reaction mixture was incubated at 37°C for 2 h in darkness. Human monomeric carbonyl reductase was added to the reaction mixture and further incubated at 37°C for 40 min. The reaction was stopped by the addition of 10 μΐ of a 20% trichloroacetic acid solution and 20 μΐ of an iodine solution (1% I 2 , 2% Kl). The amount of biopterin in the resulting supernatant was measured by the method of Fukushima and Nixon (2 1 ). No biopterin was produced in the resulting supernatant.
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